Grupo Espanol de Tumores Neuroendocrinos

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 3 drugs with upcoming expirations

Activity

Key Events

Sep 23, 2026TrialDescriptive Observational Epidemiological Study on the Characteristics of Thyroid Cancer in Patients Treated in Oncology Services of Spanish Centers: National Registry of Thyroid Cancer - Differentiated, Medullary and Anaplastic

Sep 19, 2026TrialPhase II Study Of Tarlatamab Alone Or In Combination With Chemotherapy In Advanced Neuroendocrine Carcinomas Of The Digestive System Or Unknown Primary Origin

Sep 17, 2026TrialA Multicenter, Open Label, Two Cohort, Single Arm, Phase II Study to Evaluate the Efficacy and Safety of the Anti-TROP2 Antibody-drug Conjugate Sacituzumab Govitecan in Patients With Advanced Differentiated and Anaplastic Thyroid Neoplasms.

Sep 17, 2026TrialRandomized Interval Assessment Trial of Lu177-Dotatate Every 8 Versus Every 16 Weeks in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors (NETs) to Lower TOxicity

Jul 30, 2025FDARobaxin — ATMEKSI

Oct 27, 2023TrialEfficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.

May 25, 2023TrialCabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer.

Jul 27, 2022FDAJatenzo — KYZATREX

4 more events

Mar 28, 2022FDAJatenzo — TLANDO

Oct 7, 2020TrialTrial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study

Oct 11, 2019TrialPlatinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.

Apr 2, 2019TrialDurvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

14 patent groups across drugs · Source: FDA Orange Book

DrugExpires

JatenzoApr 14, 2026 Jatenzo3 patentsJan 6, 2027 GocovriJan 22, 2028 Jatenzo4 patentsJan 8, 2029 Gocovri7 patentsMar 13, 2030 Jatenzo16 patentsApr 12, 2030 Jatenzo2 patentsMar 15, 2033 Gocovri3 patentsJun 17, 2034

6 more

JatenzoNov 28, 2037 Gocovri10 patentsFeb 15, 2038 Jatenzo3 patentsFeb 21, 2039 JatenzoOct 16, 2040 Jatenzo3 patentsMar 29, 2041 RobaxinOct 9, 2044

Regulatory

Regulatory Timeline

19827 events

FDAJan 1

Nascobal — RUBIVITE

Application NDA010791 (NDA)

FDAJan 1

Nascobal — RUBRAMIN PC

Application NDA006799 (NDA)

FDAJan 1

Nascobal — VI-TWEL

Application NDA007012 (NDA)

FDAJan 1

Nascobal — CYANOCOBALAMIN

Application NDA007085 (NDA)

FDAJan 1

Nascobal — BERUBIGEN

Application NDA006798 (NDA)

FDAJan 1

Robaxin — ROBAXIN

Application NDA011011 (NDA)

FDAJan 1

Robaxin — ROBAXIN

Application NDA011790 (NDA)

19961 event

FDANov 5

Nascobal — NASCOBAL

Application NDA019722 (NDA)

19981 event

FDASep 25

Valstar Preservative Free — VALSTAR PRESERVATIVE FREE

Application NDA020892 (NDA)

20011 event

FDANov 8

Frova — FROVA

Application NDA021006 (NDA)

20051 event

FDAJan 31

Nascobal — NASCOBAL

Application NDA021642 (NDA)

20071 event

FDAJul 27

Nascobal — CALOMIST

Application NDA022102 (NDA)

20101 event

FDAFeb 2

Xiaflex — XIAFLEX

Application BLA125338 (BLA)

20141 event

FDAMar 5

Jatenzo — AVEED

Application NDA022219 (NDA)

20171 event

FDAAug 24

Gocovri — GOCOVRI

Application NDA208944 (NDA)

20181 event

FDAFeb 16

Gocovri — OSMOLEX ER

Application NDA209410 (NDA)

20191 event

FDAMar 27

Jatenzo — JATENZO

Application NDA206089 (NDA)

20222 events

FDAJul 27

Jatenzo — KYZATREX

Application NDA213953 (NDA)

FDAMar 28

Jatenzo — TLANDO

Application NDA208088 (NDA)

20251 event

FDAJul 30

Robaxin — ATMEKSI

Application NDA219843 (NDA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)